Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy

Journal of Medical Virology

Volumn 84, Issue 2, 2012, Pages 217-222

  Lee, Sae Hwan ^a   Kim, Hong Soo ^a   Byun, In Seon ^a   Jeong, Soung Won ^a   Kim, Sang Gyune ^a   Jang, Jae Young ^a   Kim, Young Seok ^a   Kim, Boo Sung ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Antiviral therapy; DPO based multiplex PCR; Hepatitis B virus; Mutant selection; Restriction fragment mass polymorphism assays

Indexed keywords

ASPARTIC ACID; LAMIVUDINE; METHIONINE; OLIGONUCLEOTIDE; TYROSINE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FOLLOW UP; HEPATITIS B; HUMAN; MALE; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; PROTEIN MOTIF; SEQUENCE ANALYSIS; VIRUS LOAD;

ADULT; AMINO ACID MOTIFS; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RNA-DIRECTED DNA POLYMERASE; SELECTION, GENETIC; VIRAL LOAD; YOUNG ADULT;

EID: 83655180906     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23191     Document Type: Article

References (27)

1. Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH. 2006. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol 21:1783-1788.
2. Chu CM. 2000. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 15:E25-E30.
3. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
4. Gutfreund KS, Williams M, George R, Bain VG, Ma MM, Yoshida EM, Villeneuve JP, Fischer KP, Tyrrell DL. 2000. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 33:469-475.
5. Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. 2004. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 19:541-546.
6. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Kim HT, Rim KS, Kang MS, Yoo W, Kim SO. 2004. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 40:837-844.
7. Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB. 2008. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods 149:76-84.
8. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M. 2002. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 37:259-265.
9. Kobayashi S, Ide T, Sata M. 2001. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 34:584-586.
10. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
11. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36:687-696.
12. Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, Yoo W, Hong SP. 2006. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 130:1144-1152.
13. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733-1745.
14. Leung N, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien R-N. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
15. Lok AS, McMahon BJ. 2009. AASLD Practice Guidelines: Chronic hepatitis B: Update 2009. Hepatology 50:1225-1241.
16. Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Kobayashi M, Ikeda K, Miyakawa Y, Kumada H. 2004. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol 74:361-366.
17. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
18. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449-455.
19. Pas SD, de Man RA, Fries E, Osterhaus AD, Niesters HG. 2002. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J Clin Virol 25:63-71.
20. Purcell RH. 1993. The discovery of the hepatitis viruses. Gastroenterology 104:955-963.
21. Ramezani A, Velayati AA, Roshan MR, Gachkar L, Banifazl M, Keyvani H, Aghakhani A. 2008. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection. Int J Infect Dis 12:252-255.
22. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL. VIRGIL Surveillance Study Group. Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010. 52:493-500.
23. Rizzetto M. 2002. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 66:435-451.
24. Roque-Afonso AM, Ferey MP, Mackiewicz V, Fki L, Dussaix E. 2003. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: Performance of CLIP sequencing and line probe assay. Antivir Ther 8:627-634.
25. Shin YM, Heo J, Kim GH, Kang DH, Song GA, Cho M, Yang US, Kim CM, Park HK, Jang HJ. 2003. Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients. Korean J Hepatol 9:1-9.
26. Woo HY, Park H, Kim BI, Jeon WK, Kim YJ. 2008. Evaluation of dual priming oligonucleotide (DPO)-based multiplex PCR for detection of HBV YMDD mutants. Arch Virol 153:2019-2025.
27. Zoulim F. 2004. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Res 64:1-15.